Fibrinolytic therapy in acute myocardial infarct

Direct PTCA is a treatment of choice in patients with acute myocardial infarction with ST segment elevations (STEMI). Fibrinolysis remains important modality of treatment in these patients. Currently, there are more then 100 tissue plasminogen activator mutants available with different fibrin specif...

Full description

Saved in:
Bibliographic Details
Published inČasopis lékařů českých Vol. 142; no. 10; p. 582
Main Authors Aschermann, M, Horák, J, Reznícek, V, Bĕlohlávek, J, Aschermann, O
Format Journal Article
LanguageCzech
Published Czech Republic 2003
Subjects
Contraindications
Humans
Myocardial Infarction - drug therapy
Plasminogen Activators - therapeutic use
Thrombolytic Therapy
Online AccessGet more information

Cover

More Information
Summary:Direct PTCA is a treatment of choice in patients with acute myocardial infarction with ST segment elevations (STEMI). Fibrinolysis remains important modality of treatment in these patients. Currently, there are more then 100 tissue plasminogen activator mutants available with different fibrin specificity. In a clinical practice, tissue-type plasminogen activator (t-PA), recombinant tissue-type plasminogen activator (rt-PA), tenecteplase (TNK-tPA) and lanoteplase (n-PA) are most important examples. Fibrinolytic treatment in STEMI patients should be used in patients presenting in first 4 hours after beginning of chest pain, when it is sure, that direct PTCA cannot be started within next 90 minutes. Concomittant therapy of acute STEMI patients consists of anticoagulans, antiplatelet and antiagregatory treatment.
ISSN:0008-7335